Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial

Eli Lilly announced positive topline results today from TRIUMPH-1 (NCT05929066), the pivotal phase 3 clinical trial evaluating retatrutide—an investigational, once-weekly glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 receptor agonist (GLP-1 RA), and glucagon triple hormone receptor agonist—in adults with obesity or overweight and at least 1 weight-related comorbidity. All doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary end points for obesity at 80 weeks, delivering clinically meaningful weight loss. The results mark a significant milestone in what is shaping up to be a watershed year for the anti-obesity medication pipeline.^1,2

Topline Results Demonstrate Unprecedented Weight Loss

For the primary end point, participants taking retatrutide 9 mg and 12 mg lost an average of 64.4 pounds (25.9%) and 70.3 pounds (28.3%), respectively, while those on the 4 mg dose, reached with just a single dose escalation step, lost an average of 47.2 pounds (19.0%). Perhaps more striking, 45.3% of participants taking retatrutide 12 mg achieved 30% or greater weight loss, a threshold long associated with bariatric surgery, and 65.3% achieved a body mass index (BMI) below 30, falling under the clinical threshold for obesity at 80 weeks.¹

For patients who continued treatment in a prespecified blinded extension, the results were even more pronounced. Participants with a baseline BMI of 35 or higher who remained on retatrutide 12 mg through 104 weeks of total treatment lost an average of 85.0 pounds (30.3%) of their body weight, which is a level of sustained, progressive weight reduction that has never before been observed with a pharmacologic agent at this scale.¹

These TRIUMPH-1 results build on a strong foundation of earlier data. Retatrutide's phase 2 trial (NCT04881760) data, published in the New England Journal of Medicine in June 2023, reported mean body weight reductions of up to 24.2% at 48 weeks with the 12 mg dose in adults with obesity without type 2 diabetes—at the time, the largest weight reduction ever reported for any anti-obesity medication in a randomized controlled trial. No weight loss plateau was observed in TRIUMPH-1, with participants continuing a weight loss trajectory through the full 80 weeks, suggesting retatrutide's glucagon receptor component may drive a degree of sustained metabolic activation not seen with dual-agonist approaches.^1,3,4

Mechanism of Action and Cardiometabolic Benefits With Retatrutide

The triple mechanism is central to what differentiates retatrutide from currently approved therapies. Unlike earlier incretin-based therapies, retatrutide not only reduces appetite but also increases energy expenditure, shifting metabolic balance toward increased fat oxidation through its glucagon receptor agonism. This dual-sided attack on the energy balance equation—suppressing caloric intake while simultaneously boosting caloric expenditure—may explain why the drug's weight loss profile approaches surgical outcomes without the irreversibility of a bariatric procedure.⁵

The cardiometabolic benefits observed in TRIUMPH-1 extend well beyond the scale. Retatrutide demonstrated significant improvements from baseline across cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP). The positive cardiometabolic data builds on results from TRANSCEND-T2D-1 (NCT06354660), which found superior hemoglobin A1c reductions in adults with type 2 diabetes. Taken together, these findings are particularly relevant for pharmacists counseling patients with obesity and comorbid cardiometabolic conditions, where systemic risk reduction is as important a treatment goal as weight loss itself.^1,6,7

What Pharmacists Should Know As Retatrutide Continues Development

The expanding evidence base for GLP-1 and incretin-class therapies has been a dominant theme in pharmacy practice discourse in recent months. At the 2026 American Pharmacists Association Annual Meeting and Exposition, Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, associate professor of pharmacy practice and director of clinical services at Ohio Northern University, delivered a session underscoring that GLP-1 receptor agonists are no longer a diabetes drug class with a useful side effect; they have become one of the most consequential drug classes in modern medicine, with an evidence base expanding faster than many pharmacists can track. Retatrutide's TRIUMPH-1 results add another chapter to that story.⁸

The safety profile of retatrutide in TRIUMPH-1 was generally consistent with other incretin-based therapies. The most common adverse events included nausea, diarrhea, constipation, and vomiting, which were generally mild to moderate in severity. Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo. Dysesthesia, a sensory disturbance, occurred in a subset of patients but was generally mild, and the majority of affected participants continued treatment.¹

Lilly plans to present detailed TRIUMPH-1 results at the 86th Annual American Diabetes Association Scientific Sessions alongside other data from the cardiometabolic pipeline. Additional phase 3 results, including data from TRIUMPH-2 in adults with obesity and type 2 diabetes and TRIUMPH-3 in those with established cardiovascular disease, are expected later this year. A regulatory submission for retatrutide is anticipated in 2026 as the full data package continues to mature. Pharmacists should stay aware of retatrutide’s clinical pipeline and prepare for its eventual FDA approval if efficacy and safety signals continue to be meaningful.¹

REFERENCES

1. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. News Release. Eli Lilly and Company. Released May 21, 2026. Accessed May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss

2. A study of retatrutide (LY3437943) in participants who have obesity or overweight (TRIUMPH-1). ClinicalTrials.gov Identifier: NCT05929066. Last Updated April 18, 2025. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT05929066

3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity—a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972

4. A study of LY3437943 in participants who have obesity or are overweight. ClinicalTrials.gov Identifier: NCT04881760. Last Updated September 13, 2023. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT04881760

5. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide–a game changer in obesity pharmacotherapy. Biomolecules. 2025;15(6):796. doi:10.3390/biom15060796

6. Halpern L. Retatrutide delivers significant hemoglobin A1C reduction, weight loss in phase 3 type 2 diabetes trial. Pharmacy Times. Published April 3, 2026. Accessed May 21, 2026. https://www.pharmacytimes.com/view/retatrutide-delivers-significant-a1c-reduction-weight-loss-in-phase-3-type-2-diabetes-trial

7. Effect of retatrutide compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone (TRANSCEND-T2D-1). ClinicalTrials.gov Identifier: NCT06354660. Last Updated March 5, 2026. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT06354660

8. Halpern L. APhA2026: GLP-1 therapies are rewriting the rules of metabolic disease. Pharmacy Times. Published March 29, 2026. Accessed May 21, 2026. https://www.pharmacytimes.com/view/apha2026-glp-1-therapies-are-rewriting-the-rules-of-metabolic-disease